Breaking News, Collaborations & Alliances

Tessa Therapeutics Enters CRADA with the National Cancer Institute

To support investigation of Tessa’s lead allogeneic cell therapy, TT11X, in several subtypes of non-Hodgkin lymphoma.

Tessa Therapeutics Ltd., a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to investigate TT11X, Tessa’s allogeneic “off-the-shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) therapy, in multiple subtypes of non-Hodgkin lymphoma. T...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters